LianBio Launches to Bring US Assets to China and Announces $719 Million in Deals • Perceptive Advisors launched LianBio, a Princeton-Shanghai company, to bring US biopharma assets to China, primarily from its own portfolio of companies; • LianBio acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement and has preferential access to BridgeBio assets; • LianBio will collaborate with MyoKardia in an $187.5 million deal to develop MyoKardia's lead cardiovascular drug in China and other Asian territories; Deals and Financings • Tianjin CanSino Biologics raised $748 million in an Shanghai STAR Board and climbed 88% in its first trading session to support its vaccines, including a Phase III COVID-19 vaccine; • Cellular Biomedicine, a Maryland-Shanghai immunotherapy and stem cell company, accepted a $383 million privatization offer; • Viva Biotech, a Shanghai drug discovery CRO, will pay $368 million to acquire an 80% stake in Zhejiang Langhua Pharma, a CDMO and API company; • Shanghai Pharma in-licensed China rights to an oncolytic virus program developed by Shenzhen's ImmVira in an $165 million agreement; • Shanghai Hanyu completed a $72 million Series D round for its cardiovascular medical devices; • MicuRx Pharma, a San Francisco-Shanghai biotech developing antimicrobial treatments, closed a $43 million Series D round from China investors; • Vision Medicals of Guangzhou raised $29 million in a Series B funding to support genetic testing services for infectious diseases; • Hangzhou AnHeart Therapeutics completed a $20 million Series A+ financing to underwrite global Phase II trials of its ROS1/NTRK inhibitor; • Suzhou Zanrong Pharma closed a $20 million Series A+ financing to develop small molecule drugs for cancer indications; • MicuRx Pharma, a US-China anti-infectives company, received $7.8 million to support development of MRX-8, a novel antimicrobial; Deals and Financings • Suzhou Innovent Biologics reported positive early data from a Phase III trial of Tyvyt®, its PD-1 drug, as a first-line treatment for patients with NSCLC. Stock Symbols: (NSDQ: BBIO) (NSDQ: MYOK) (HK: 6185; SHA: 688185) (NSDQ: CBMG) (SHA: 601607; HK :02067) (HK: 01801) Share this with colleagues: // //